Cargando…

Voltage-Gated Potassium Channel Kv1.3 as a Target in Therapy of Cancer

Voltage-gated potassium channel Kv1.3 is an integral membrane protein, which is selectively permeable for potassium ions and is activated upon a change of membrane potential. Channel activation enables transportation of potassium ions down their electrochemical gradient. Kv1.3 channel is expressed i...

Descripción completa

Detalles Bibliográficos
Autores principales: Teisseyre, Andrzej, Palko-Labuz, Anna, Sroda-Pomianek, Kamila, Michalak, Krystyna
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Frontiers Media S.A. 2019
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6769076/
https://www.ncbi.nlm.nih.gov/pubmed/31612103
http://dx.doi.org/10.3389/fonc.2019.00933
_version_ 1783455177374695424
author Teisseyre, Andrzej
Palko-Labuz, Anna
Sroda-Pomianek, Kamila
Michalak, Krystyna
author_facet Teisseyre, Andrzej
Palko-Labuz, Anna
Sroda-Pomianek, Kamila
Michalak, Krystyna
author_sort Teisseyre, Andrzej
collection PubMed
description Voltage-gated potassium channel Kv1.3 is an integral membrane protein, which is selectively permeable for potassium ions and is activated upon a change of membrane potential. Channel activation enables transportation of potassium ions down their electrochemical gradient. Kv1.3 channel is expressed in many cell types, both normal and cancer. Activity of the channel plays an important role in cell proliferation and apoptosis. Inhibition of Kv1.3 channel may be beneficial in therapy of several diseases including some cancer disorders. This review focuses on Kv1.3 channel as a new potentially attractive molecular target in cancer therapy. In the first part, changes in the channel expression in selected cancer disorders are described. Then, the role of the channel activity in cancer cell proliferation and apoptosis is presented. Finally, it is shown that some low molecular weight organic inhibitors of the channel including selected biologically active plant-derived polycyclic compounds may selectively induce apoptosis of Kv1.3-expressing cancer cells while sparing normal cells and healthy organs. These compounds may be promising candidates for putative application in therapy of some cancer disorders, such as melanoma, pancreatic ductal adenocarcinoma (PDAC), or B-type chronic lymphocytic leukemia (B-CLL).
format Online
Article
Text
id pubmed-6769076
institution National Center for Biotechnology Information
language English
publishDate 2019
publisher Frontiers Media S.A.
record_format MEDLINE/PubMed
spelling pubmed-67690762019-10-14 Voltage-Gated Potassium Channel Kv1.3 as a Target in Therapy of Cancer Teisseyre, Andrzej Palko-Labuz, Anna Sroda-Pomianek, Kamila Michalak, Krystyna Front Oncol Oncology Voltage-gated potassium channel Kv1.3 is an integral membrane protein, which is selectively permeable for potassium ions and is activated upon a change of membrane potential. Channel activation enables transportation of potassium ions down their electrochemical gradient. Kv1.3 channel is expressed in many cell types, both normal and cancer. Activity of the channel plays an important role in cell proliferation and apoptosis. Inhibition of Kv1.3 channel may be beneficial in therapy of several diseases including some cancer disorders. This review focuses on Kv1.3 channel as a new potentially attractive molecular target in cancer therapy. In the first part, changes in the channel expression in selected cancer disorders are described. Then, the role of the channel activity in cancer cell proliferation and apoptosis is presented. Finally, it is shown that some low molecular weight organic inhibitors of the channel including selected biologically active plant-derived polycyclic compounds may selectively induce apoptosis of Kv1.3-expressing cancer cells while sparing normal cells and healthy organs. These compounds may be promising candidates for putative application in therapy of some cancer disorders, such as melanoma, pancreatic ductal adenocarcinoma (PDAC), or B-type chronic lymphocytic leukemia (B-CLL). Frontiers Media S.A. 2019-09-24 /pmc/articles/PMC6769076/ /pubmed/31612103 http://dx.doi.org/10.3389/fonc.2019.00933 Text en Copyright © 2019 Teisseyre, Palko-Labuz, Sroda-Pomianek and Michalak. http://creativecommons.org/licenses/by/4.0/ This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) and the copyright owner(s) are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms.
spellingShingle Oncology
Teisseyre, Andrzej
Palko-Labuz, Anna
Sroda-Pomianek, Kamila
Michalak, Krystyna
Voltage-Gated Potassium Channel Kv1.3 as a Target in Therapy of Cancer
title Voltage-Gated Potassium Channel Kv1.3 as a Target in Therapy of Cancer
title_full Voltage-Gated Potassium Channel Kv1.3 as a Target in Therapy of Cancer
title_fullStr Voltage-Gated Potassium Channel Kv1.3 as a Target in Therapy of Cancer
title_full_unstemmed Voltage-Gated Potassium Channel Kv1.3 as a Target in Therapy of Cancer
title_short Voltage-Gated Potassium Channel Kv1.3 as a Target in Therapy of Cancer
title_sort voltage-gated potassium channel kv1.3 as a target in therapy of cancer
topic Oncology
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6769076/
https://www.ncbi.nlm.nih.gov/pubmed/31612103
http://dx.doi.org/10.3389/fonc.2019.00933
work_keys_str_mv AT teisseyreandrzej voltagegatedpotassiumchannelkv13asatargetintherapyofcancer
AT palkolabuzanna voltagegatedpotassiumchannelkv13asatargetintherapyofcancer
AT srodapomianekkamila voltagegatedpotassiumchannelkv13asatargetintherapyofcancer
AT michalakkrystyna voltagegatedpotassiumchannelkv13asatargetintherapyofcancer